Financial Survey: KalVista Pharmaceuticals (NASDAQ:KALV) and CNS Pharmaceuticals (NASDAQ:CNSP)

CNS Pharmaceuticals (NASDAQ:CNSP) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for CNS Pharmaceuticals and KalVista Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	0	1	0	1	3.00
KalVista Pharmaceuticals	0	0	7	1	3.13

CNS Pharmaceuticals currently has a consensus target price of $25.00, suggesting a potential upside of 2,172.73%. KalVista Pharmaceuticals has a consensus target price of $24.83, suggesting a potential upside of 131.87%. Given CNS Pharmaceuticals’ higher possible upside, equities research analysts clearly believe CNS Pharmaceuticals is more favorable than KalVista Pharmaceuticals.

Valuation & Earnings

This table compares CNS Pharmaceuticals and KalVista Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$18.85 million	($3,748.50)	0.00
KalVista Pharmaceuticals	N/A	N/A	-$126.64 million	($3.72)	-2.88

KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CNS Pharmaceuticals and KalVista Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	N/A	-515.32%
KalVista Pharmaceuticals	N/A	-103.92%	-88.06%

Institutional & Insider Ownership

14.0% of CNS Pharmaceuticals shares are held by institutional investors. 0.1% of CNS Pharmaceuticals shares are held by company insiders. Comparatively, 10.5% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

CNS Pharmaceuticals has a beta of 2.72, suggesting that its stock price is 172% more volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500.

Summary

CNS Pharmaceuticals beats KalVista Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.